| Name | Nebivolol hydrochloride |
| Description | Nebivolol hydrochloride (R 065824 hydrochloride) is a cardioselective ADRENERGIC BETA-1 RECEPTOR ANTAGONIST (beta-blocker) that functions as a VASODILATOR through the endothelial L-arginine/ NITRIC OXIDE system. It is used to manage HYPERTENSION and chronic HEART FAILURE in elderly patients. |
| Cell Research | Cells are exposed to different concentrations of Nebivolol (10-7~10-5 M) for 1, 2, 4, 7 and 14 days. Cell proliferation is analyzed by bromodeoxyuridine (BrdU) incorporation, and cell apoptosis is detected by PI or annexin V staining.(Only for Reference) |
| In vitro | Nebivolol treatment of rats with myocardial infarction lowered mean blood pressure by a small amount. Nebivolol reduced myocardial apoptosis in rats with myocardial infarction when administered intravenously for 10 minutes followed by oral administration. |
| In vivo | Nebivolol reduced the proliferation of coronary smooth muscle cells (haCSMCs) and endothelial cells (haECs) in a concentration- and time-dependent manner.Nebivolol acted with high affinity and selectivity at the beta 1-adrenergic receptor site in the preparation of rabbit lung membranes.Nebivolol treatment of haCSMCs for 7 days significantly inhibited cell proliferation (IC50 ~ 10 μM). Nebivolol treated haCSMCs for 7 days, significantly inhibited cell proliferation (IC50: 6.1 μM). nebivolol treated haCSMCs for 48 hours, the apoptosis rate was 23%, and reduced the number of S-phase cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 4.4 mg/mL (9.96 mM), Sonication is recommended.
DMSO : 60 mg/mL (135.78 mM), Sonication is recommended.
|
| Keywords | β1-adrenoceptor | vasodilator | R65824 | R-065824 Hydrochloride | R065824 Hydrochloride | R-065824 | R065824 | R 65824 | R 065824 Hydrochloride | R 065824 | oral | Nebivolol hydrochloride | Nebivolol Hydrochloride | Nebivolol | ischemic heart disease | Inhibitor | inhibit | hypertension | coronary artery disease | congestive heart failure | Beta Receptor | Apoptosis | AdrenergicReceptor | Adrenergic Receptor | adrenergic blocking |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Metronidazole | Sorafenib | Tributyrin | L-Ascorbic acid sodium salt | Salicylic acid |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
